Prima BioMed (NASDAQ:IMMP) Share Price Passes Above Fifty Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.40 and traded as high as $0.4104. Prima BioMed shares last traded at $0.3922, with a volume of 153,277 shares trading hands.

Analyst Ratings Changes

IMMP has been the topic of a number of recent research reports. Maxim Group raised Prima BioMed from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a research note on Friday, July 10th. Finally, Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Prima BioMed currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Prima BioMed Trading Down 0.3%

The company has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $1.09.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC raised its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. 2.32% of the stock is currently owned by institutional investors.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.